Table 2.

Results from a Clinical Trial Comparing Methotrexate and Mycophenolate Mofetil for Non-Infectious Uveitis

Patient Level	Methotrexate (N=35)	Mycophenolate Mofetil (N=32)	p-value
Treatment Success N(%)	24 (69)	15 (47)	0.09
Treatment Failure N(%)	11 (31)	17 (53)
Reason for treatment failure N(%)
Lack of efficacy*	7 (63)	15 (88)
Intolerability	3 (27)	2 (12)
Safety concern	1 (9)	0 (0)
Success by Anatomic Location N(%)
Anterior & Intermediate/Intermediate	2/3 (67)	5/10 (50)	0.99
Posterior/Panuveitis	22/32 (69)	10/22 (45)	0.10
Time to corticosteroid-sparing control of inflammation (days)**
Median (IQR)	139 (62.5–142)	124 (60–156)	0.44
Medication Compliance N(%)
Missed at least one dose	13 (32)	17 (44)	0.97
Eye Level	Methotrexate (E=68)	Mycophenolate Mofetil (E=56)	p-value
Mean change in visual acuity***			0.68
logMAR (SD)	−0.26 (0.33)	−0.19 (0.36)
Macular Edema Resolution N(%)	17/22 (77)	7/13 (54)	0.31

^*Did not meet definition of corticosteroid-sparing controlled inflammation at 5 and 6 month visits

^**Time for those who met the definition of treatment success

^***Best-corrected visual acuity of uveitic eyes only

IQR = interquartile range; SD = standard deviation logMAR = logarithm of the minimum angle of resolution